Dual Specificity Mitogen Activated Protein Kinase Kinase 2 (ERK Activator Kinase 2 or MAPK/ERK Kinase 2 or MAP2K2 or EC 2.7.12.2) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Dual Specificity Mitogen Activated Protein Kinase Kinase 2 (ERK Activator Kinase 2 or MAPK/ERK Kinase 2 or MAP2K2 or EC 2.7.12.2) - Pipeline Review, H2 2016

Dual Specificity Mitogen Activated Protein Kinase Kinase 2 (ERK Activator Kinase 2 or MAPK/ERK Kinase 2 or MAP2K2 or EC 2.7.12.2) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Dual Specificity Mitogen Activated Protein Kinase Kinase 2 (ERK Activator Kinase 2 or MAPK/ERK Kinase 2 or MAP2K2 or EC 2.7.12.2) - Pipeline Review, H2 2016
Published Jul 20, 2016
106 pages — Published Jul 20, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Dual Specificity Mitogen Activated Protein Kinase Kinase 2 (ERK Activator Kinase 2 or MAPK/ERK Kinase 2 or MAP2K2 or EC 2.7.12.2) - Pipeline Review, H2 2016, provides in depth analysis on Dual Specificity Mitogen Activated Protein Kinase Kinase 2 (ERK Activator Kinase 2 or MAPK/ERK Kinase 2 or MAP2K2 or EC 2.7.12.2) targeted pipeline therapeutics.

The report provides comprehensive information on the Dual Specificity Mitogen Activated Protein Kinase Kinase 2 (ERK Activator Kinase 2 or MAPK/ERK Kinase 2 or MAP2K2 or EC 2.7.12.2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Dual Specificity Mitogen Activated Protein Kinase Kinase 2 (ERK Activator Kinase 2 or MAPK/ERK Kinase 2 or MAP2K2 or EC 2.7.12.2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Dual Specificity Mitogen Activated Protein Kinase Kinase 2 (ERK Activator Kinase 2 or MAPK/ERK Kinase 2 or MAP2K2 or EC 2.7.12.2)
- The report reviews Dual Specificity Mitogen Activated Protein Kinase Kinase 2 (ERK Activator Kinase 2 or MAPK/ERK Kinase 2 or MAP2K2 or EC 2.7.12.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Dual Specificity Mitogen Activated Protein Kinase Kinase 2 (ERK Activator Kinase 2 or MAPK/ERK Kinase 2 or MAP2K2 or EC 2.7.12.2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Dual Specificity Mitogen Activated Protein Kinase Kinase 2 (ERK Activator Kinase 2 or MAPK/ERK Kinase 2 or MAP2K2 or EC 2.7.12.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related t

  
Source:
Document ID
GMDHC0406TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents25
  List of Tables51
  List of Figures61
Introduction71
  Global Markets Direct Report Coverage71
Dual Specificity Mitogen Activated Protein Kinase Kinase 2 (ERK Activator Kinase 2 or MAPK/ERK Kinase 2 or MAP2K2 or EC 2.7.12.2) Overview81
Therapeutics Development94
  Dual Specificity Mitogen Activated Protein Kinase Kinase 2 (ERK Activator Kinase 2 or MAPK/ERK Kinase 2 or MAP2K2 or EC 2.7.12.2) Products under Development by Stage of Development91
  Dual Specificity Mitogen Activated Protein Kinase Kinase 2 (ERK Activator Kinase 2 or MAPK/ERK Kinase 2 or MAP2K2 or EC 2.7.12.2) Products under Development by Therapy Area101
  Dual Specificity Mitogen Activated Protein Kinase Kinase 2 (ERK Activator Kinase 2 or MAPK/ERK Kinase 2 or MAP2K2 or EC 2.7.12.2) Products under Development by Indication112
Dual Specificity Mitogen Activated Protein Kinase Kinase 2 (ERK Activator Kinase 2 or MAPK/ERK Kinase 2 or MAP2K2 or EC 2.7.12.2) Pipeline Products Glance132
  Late Stage Products131
  Early Stage Products141
Dual Specificity Mitogen Activated Protein Kinase Kinase 2 (ERK Activator Kinase 2 or MAPK/ERK Kinase 2 or MAP2K2 or EC 2.7.12.2) Products under Development by Companies155
Dual Specificity Mitogen Activated Protein Kinase Kinase 2 (ERK Activator Kinase 2 or MAPK/ERK Kinase 2 or MAP2K2 or EC 2.7.12.2) Therapeutics Assessment206
  Assessment by Monotherapy/Combination Products201
  Assessment by Mechanism of Action211
  Assessment by Route of Administration222
  Assessment by Molecule Type242
Dual Specificity Mitogen Activated Protein Kinase Kinase 2 (ERK Activator Kinase 2 or MAPK/ERK Kinase 2 or MAP2K2 or EC 2.7.12.2) Companies Involved in Therapeutics Development269
  Array BioPharma Inc.261
  AstraZeneca Plc271
  Confluence Life Sciences, Inc.281
  F. Hoffmann-La Roche Ltd.291
  GlaxoSmithKline Plc301
  Merck &Co., Inc.311
  Merck KGaA321
  Novartis AG332
Dual Specificity Mitogen Activated Protein Kinase Kinase 2 (ERK Activator Kinase 2 or MAPK/ERK Kinase 2 or MAP2K2 or EC 2.7.12.2) Drug Profiles3544
  binimetinib Drug Profile357
  binimetinib + encorafenib Drug Profile422
  CDD-450 Drug Profile441
  CIP-137401 Drug Profile451
  cobimetinib fumarate Drug Profile466
  dabrafenib mesylate + durvalumab + trametinib dimethyl sulfoxide Drug Profile521
  dabrafenib mesylate + panitumumab + trametinib dimethyl sulfoxide Drug Profile531
  dabrafenib mesylate + trametinib dimethyl sulfoxide Drug Profile547
  MK-2206 + selumetinib sulfate Drug Profile611
  pimasertib hydrochloride Drug Profile623
  pimasertib hydrochloride + voxtalisib Drug Profile652
  selumetinib sulfate Drug Profile675
  trametinib dimethyl sulfoxide Drug Profile725
  trametinib dimethyl sulfoxide + uprosertib Drug Profile772
Dual Specificity Mitogen Activated Protein Kinase Kinase 2 (ERK Activator Kinase 2 or MAPK/ERK Kinase 2 or MAP2K2 or EC 2.7.12.2) Dormant Projects798
Dual Specificity Mitogen Activated Protein Kinase Kinase 2 (ERK Activator Kinase 2 or MAPK/ERK Kinase 2 or MAP2K2 or EC 2.7.12.2) Discontinued Products872
Dual Specificity Mitogen Activated Protein Kinase Kinase 2 (ERK Activator Kinase 2 or MAPK/ERK Kinase 2 or MAP2K2 or EC 2.7.12.2) Featured News &Press Releases8916
  Jun 30, 2016: Array BioPharma Submits Binimetinib New Drug Application to U.S. FDA891
  Jun 06, 2016: Array Presents Full Results from Phase 3 NEMO Study901
  Jun 06, 2016: Novartis combination therapy Tafinlar + Mekinist demonstrates overall survival benefit at three-year follow-up in patients with advanced melanoma911
  Jun 06, 2016: Novartis pivotal data for Tafinlar + Mekinist demonstrated a 63 percent overall response rate in treating rare form of lung cancer921
  Jun 05, 2016: Exelixis Announces Genentech Presentation of Preliminary Phase 1B Trial Results for the Combination of Cobimetinib and Atezolizumab at ASCO 2016 Annual Meeting931
  Jun 03, 2016: Cobimetinib in advanced melanoma with BRAF V600 mutation: Added benefit now considerable941
  May 18, 2016: Array BioPharma Announces Key Data from NRAS-mutant Melanoma at ASCO 2016951
  May 12, 2016: Selumetinib granted Orphan Drug Designation in the US for adjuvant treatment of differentiated thyroid cancer961
  Apr 29, 2016: NICE recommends combined drug therapy proven to extend life for skin cancer971
  Apr 20, 2016: Exelixis Announces Presentation On Cobimetinib At 2016 ASCO Annual Meeting972
  Apr 01, 2016: Array BioPharma Announces Decision To Discontinue MILO Study In Ovarian Cancer991
  Mar 22, 2016: Many Targeted Cancer Therapies Suppress T Cell Immune Responses991
  Feb 25, 2016: New targeted therapy for treatment of serious form of skin cancer approved in Canada1002
  Jan 13, 2016: Dabrafenib/trametinib in advanced BRAF V600 mutated melanoma: Indication of added benefit1021
  Dec 16, 2015: Array BioPharma Announces Phase 3 Binimetinib Trial Meets Primary Endpoint For NRAS-Mutant Melanoma1032
Appendix1052
  Methodology1051
  Coverage1051
  Secondary Research1051
  Primary Research1051
  Expert Panel Validation1051
  Contact Us1051
  Disclaimer1061

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Dual Specificity Mitogen Activated Protein Kinase Kinase 2 (ERK Activator Kinase 2 or MAPK/ERK Kinase 2 or MAP2K2 or EC 2.7.12.2) - Pipeline Review, H2 2016" Jul 20, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Dual-Specificity-Mitogen-Activated-Protein-Kinase-Kinase-2-ERK-Activator-Kinase-2-or-MAPK-ERK-Kinase-2-or-MAP2K2-or-EC-2-7-12-2-Pipeline-Review-H2-2016-2088-16288>
  
APA:
Global Markets Direct - Market Research. (2016). Dual Specificity Mitogen Activated Protein Kinase Kinase 2 (ERK Activator Kinase 2 or MAPK/ERK Kinase 2 or MAP2K2 or EC 2.7.12.2) - Pipeline Review, H2 2016 Jul 20, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Dual-Specificity-Mitogen-Activated-Protein-Kinase-Kinase-2-ERK-Activator-Kinase-2-or-MAPK-ERK-Kinase-2-or-MAP2K2-or-EC-2-7-12-2-Pipeline-Review-H2-2016-2088-16288>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.